{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:28:59Z","timestamp":1793896139055,"version":"4.8.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a clinical syndrome characterized by nasal polyposis, asthma, and intolerance to aspirin\/NSAID. It affects approximately 15% cases of severe asthma, 10% of nasal polyps and 9% of rhinosinusitis. N-ERD results in associated asthma exacerbations, oral corticosteroids bursts, corticosteroid-dependent disease, and multiple endoscopic sinus surgeries. Unknown influences cause polyp epithelium to release alarmins, such as IL-33 and TSLP. These cytokines activate lymphoid cells, both Th2 and ILC2, to release cytokines such as IL5, IL4 and IL13, resulting in complex type 2 inflammation involving mast cells, eosinophils and platelets. Arachidonic acid released from such cells is metabolized into mediators. N-ERD is characterized by an imbalance in eicosanoid levels, especially CysLTs, PDG and PGE2. Patients with N-ERD present nasal symptoms (congestion, hyposmia\/anosmia, nasal discharge) and lower airways symptoms (cough, sneezing, shortness of breath, chest tightness), anosmia, severe hyposmia as well as severe asthma which impacts the quality of life in this disease and leads to safety concerns in patients daily lives. Despite the variety of treatment strategies, the likelihood of recurrence of symptoms is high in patients with N-ERD. The most important strategies for treating N-ERD are listed as following: drug therapies, aspirin desensitization, monoclonal antibodies and other therapies associated. N-ERD treatment remains a major challenge in the current situation. Selecting the appropriate patient for aspirin desensitization, monoclonal antibodies or both is essential. This review provides an overview on aspirin desensitization and biologics in N-ERD and might help in decision making from both the perspective of the physician and patient. Patient characteristics, safety, efficacy, health care costs, but also patient preferences are all factors to take into account when it comes to a choice between biologics or aspirin desensitization.<\/jats:p>","DOI":"10.3389\/falgy.2023.1080951","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T05:01:29Z","timestamp":1681275689000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?"],"prefix":"10.3389","volume":"4","author":[{"given":"Dorien","family":"Van Broeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brecht","family":"Steelant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenis","family":"Scadding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.wjorl.2020.07.009","article-title":"Aspirin-exacerbated respiratory disease: update on medical management","volume":"6","author":"White","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","article-title":"The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a work group report from the rhinitis, rhinosinusitis and ocular allergy committee of the American academy of allergy, asthma & immunology","volume":"147","author":"Stevens","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-Exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.jaip.2022.01.039","article-title":"SWOT Analysis of chronic rhinosinusitis care anno 2022","volume":"10","author":"Hellings","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1398-9995.1984.tb02621.x","article-title":"Aspirin tolerance induced in aspirin-sensitive asthmatics","volume":"39","author":"Kowalski","year":"1984","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0091-6749(80)90143-8","article-title":"Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges","volume":"66","author":"Stevenson","year":"1980","journal-title":"J Allergy Clin Immunol"},{"key":"B7","author":"Simon","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","first-page":"734733","DOI":"10.3389\/falgy.2021.734733","article-title":"Pathomechanisms of AERD-recent advances","volume":"2","author":"Lyly","year":"2021","journal-title":"Front Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D\u2082: a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"889221","DOI":"10.3389\/falgy.2022.889221","article-title":"White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA","volume":"3","author":"De Prins","year":"2022","journal-title":"Front Allergy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4193\/Rhin20.570","article-title":"State-of-the-art overview on biological treatment for CRSwNP","volume":"59","author":"Hellings","year":"2021","journal-title":"Rhinology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/alr.22643","article-title":"Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease","volume":"11","author":"Sweis","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.anai.2020.08.008","article-title":"Aspirin desensitization vs biologics for patients with aspirin-exacerbated respiratory disease","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2021.12.030","article-title":"Controversies in allergy: aspirin desensitization or biologics for aspirin-exacerbated respiratory disease-how to choose","volume":"10","author":"Laidlaw","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA Consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA Expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.iac.2012.10.002","article-title":"Aspirin-exacerbated respiratory disease: clinical disease and diagnosis","volume":"33","author":"Bochenek","year":"2013","journal-title":"Immunol Allergy Clin North Am"},{"key":"B19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/0091-6749(83)90440-2","article-title":"Aspirin-sensitive rhinosinusitis: the clinical syndrome and effects of aspirin administration","volume":"71","author":"Lumry","year":"1983","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European Position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","article-title":"Survey-Defined patient experiences with aspirin-exacerbated respiratory disease","volume":"3","author":"Ta","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/01.MLG.0000166702.38850.1B","article-title":"Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial","volume":"115","author":"Parikh","year":"2005","journal-title":"Laryngoscope"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1136\/thorax.55.suppl_2.s75","article-title":"Effects of lysine-acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies","volume":"55","author":"Nucera","year":"2000","journal-title":"Thorax"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1017\/S0022215107000515","article-title":"Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma","volume":"121","author":"Ogata","year":"2007","journal-title":"J Laryngol Otol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1586\/1744666X.2014.901889","article-title":"Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis","volume":"10","author":"Parikh","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B29","first-page":"588","article-title":"Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis","volume":"67","author":"Patriarca","year":"1991","journal-title":"Ann Allergy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00405-021-07063-2","article-title":"A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease","volume":"279","author":"Pendolino","year":"2022","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1939-4551-7-18","article-title":"Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease","volume":"7","author":"Howe","year":"2014","journal-title":"World Allergy Organ J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.7326\/0003-4819-150-6-200903170-00006","article-title":"Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding","volume":"150","author":"Steinhubl","year":"2009","journal-title":"Ann Intern Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/alr.22709","article-title":"Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: clinical perspective","volume":"11","author":"Bosso","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaci.2007.06.047","article-title":"An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"121","author":"Shaker","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5R\u03b1 in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2020.11.001","article-title":"Inflammatory heterogeneity in aspirin-exacerbated respiratory disease","volume":"147","author":"Scott","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.anai.2022.04.004","article-title":"Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps","volume":"129","author":"Borish","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jaci.2021.06.019","article-title":"Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.jaip.2020.09.007","article-title":"Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: a case series","volume":"9","author":"Martin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaip.2021.09.050","article-title":"Omalizumab-Induced aspirin tolerance in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease patients is independent of atopic sensitization","volume":"10","author":"Quint","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B44","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jaci.2021.10.029","article-title":"Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)","volume":"149","author":"Scadding","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/alr.22865","article-title":"Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease","volume":"11","author":"Yong","year":"2021","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1080951\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T05:01:31Z","timestamp":1681275691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1080951\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":45,"alternative-id":["10.3389\/falgy.2023.1080951"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2023.1080951","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"article-number":"1080951"}}